Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Elicio Therapeutics, Inc. (NASDAQ: ELTX) is a clinical-stage biotechnology company dedicated to developing a new class of potent immunotherapies. Their proprietary Amphiphile (AMP) platform is designed to deliver immunogens, including checkpoint agonists, and adjuvants directly to the lymph nodes. This targeted delivery aims to enhance the body's immune response, particularly T cell activity, to fight cancers and other diseases. Elicio's pipeline includes ELI-002, an AMP-KRAS vaccine for KRAS-driven cancers currently in clinical trials, as well as other candidates targeting various mutations and diseases.
Primary hub for research and development, corporate operations, and strategic management.
Located within the One Kendall Square complex, a prominent center for life science and technology companies, offering modern laboratory and office facilities.
A dynamic, innovative, and science-driven environment focused on collaboration and advancing groundbreaking immunotherapies. Employees are typically mission-oriented, working towards developing treatments for serious diseases.
Kendall Square in Cambridge is a leading global biotechnology hub, providing Elicio Therapeutics with access to a rich ecosystem of talent, research institutions (like MIT and Harvard), potential partners, and investors.
Elicio Therapeutics is primarily based in the United States, with its research, development, and corporate operations headquartered in Cambridge, MA. While its core R&D and administrative functions are U.S.-centric, the company's clinical trials for its therapeutic candidates, such as ELI-002, are conducted at sites in multiple countries. This gives Elicio an operational reach for its clinical development programs beyond the U.S., engaging with international medical centers and patient populations.
One Kendall Square, Suite B14202
Cambridge
MA
United States
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Elicio Therapeutics' leadership includes:
Elicio Therapeutics has been backed by several prominent investors over the years, including:
Elicio Therapeutics strengthened its executive team over the past year with a key appointment in its financial leadership, following a planned transition. These changes support the company's progression through clinical development and strategic growth.
Discover the tools Elicio Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Elicio Therapeutics primarily uses the [first_initial][last]@elicio.com email format for its employees. Variations may exist, but this is the most commonly observed pattern.
[first_initial][last]@elicio.com
Format
jdoe@elicio.com
Example
85%
Success rate
Business Wire • May 20, 2024
Elicio Therapeutics announced that results from its Phase 1 AMPLIFY-201 study of ELI-002 were published in Nature Medicine. The study showed ELI-002, an investigational therapeutic vaccine, induced robust T cell responses and anti-tumor effects in patients with KRAS-mutated solid tumors....more
GlobeNewswire • May 14, 2024
Elicio Therapeutics reported its financial results for the first quarter of 2024 and provided updates on its clinical programs, including advancements with ELI-002 and other pipeline candidates targeting mKRAS-driven cancers....more
GlobeNewswire • April 2, 2024
Elicio announced the dosing of the first patient in its Phase 1a AMPLIFY-7P study evaluating ELI-007, an AMP-modified CpG adjuvant combined with other anti-cancer agents, for patients with relapsed/refractory KRAS/NRAS mutated solid tumors....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Elicio Therapeutics, are just a search away.